Triomics, a developer of an AI-powered platform designed to streamline data-heavy workflows for oncologists and administrative staff, has raised a $22 million Series B round. The company previously secured a $15 million Series A in 2024.
The funding underscores growing investor appetite for artificial intelligence tools that can reduce the administrative burden on healthcare professionals. By automating tasks such as patient data extraction and documentation, the platform aims to free clinicians to focus more on direct patient care.
The Series B brings Triomics' total disclosed funding to at least $37 million. The company has not disclosed the lead investor or valuation for the latest round. The startup plans to use the capital to expand its engineering team and accelerate product deployment in U.S. cancer centers.
If successful, Triomics could help address a key pain point in oncology: the time spent on manual data entry and record-keeping. However, the health-tech sector remains crowded, and regulatory hurdles for AI in clinical settings could slow adoption.
"AI tools in healthcare still face skepticism around accuracy and integration," cautioned one industry analyst, speaking on condition of anonymity due to lack of authorization.